Skip to main content Help with accessibility Skip to main navigation

TICAGRELOR tablets (Brilique®) to prevent thrombotic events post intracranial stenting

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 27 - Jan - 2022
Body System:
Amber initiated
TICAGRELOR tablets (Brilique®) to prevent thrombotic events post intracranial stenting

The Pan Mersey Area Prescribing Committee recommends the prescribing of TICAGRELOR tablets (Brilique®), following specialist initiation, to prevent thrombotic events post intracranial stenting.